Vasolin / SlavinormВазолин / Славинорм
Slavinorm is an injectable calf-vessel polypeptide complex studied for vascular disease. The St. Petersburg Institute of Bioregulation and Gerontology developed the experimental preparation described in early animal studies. Vesugen is the defined KED tripeptide.
What the studies found
Randomized study in people · 2023
Slavinorm for intermittent claudication: randomized placebo-controlled trial
- Pain-free walking distance
- Active arms: +46.2% and +31.4%; placebo: +6.5%.
- At least 50% walking-distance improvement
- 28% and 26% in active arms versus 3% with placebo; exact analysis denominators unavailable.
- Adverse-event comparison
- p=0.59983; event counts absent.
Pain-free walking distance rose 46.2% and 31.4% in the two Slavinorm groups versus 6.5% with placebo.
Study notes · methods, sources and limitations
Participants or model 108 randomized patients; active groups 36/36, placebo groups 18/18
Design Seven-center, double-blind trial with 108 randomized participants. The two Slavinorm groups (36 each) received 5 mg intramuscularly twice or three times weekly for 10 injections. The two placebo groups (18 each) followed the matching schedules.
Important limitations
- The abstract does not resolve analysis populations, placebo pooling, allocation concealment or missing data. No exact primary-outcome p value or confidence interval is supplied. A nonsignificant adverse-event comparison does not establish safety equivalence.
- The abstract reports one placebo result across two placebo arms and provides no pooling method. Follow-up lasted up to 91 days. Long-term walking outcomes and detailed adverse-event counts are unavailable in the abstract.
Angiology and Vascular Surgery. 29(1):23–33 · Original clinical journal publication
Comparison in people · 2025
Slavinorm in peripheral arterial atherosclerosis: 78-patient comparison
- Ankle–brachial index
- Both groups: 0.7→0.8 at two months; at three months active remained 0.8, comparator fell to 0.7.
- Walking distance in active group
- 22/38 gained 35–40 m; 4/38 unchanged. The paper prints the range for the remaining 12 participants in reverse order.
- Harms
- Authors report no adverse reactions; ascertainment and longer follow-up remain unresolved.
At three months the ankle–brachial index was 0.8 with Slavinorm and 0.7 with pentoxifylline. In the Slavinorm group, 22 of 38 participants walked 35–40 m farther.
Study notes · methods, sources and limitations
Participants or model 78 patients: 38 Slavinorm plus baseline care, 40 comparator; diabetes excluded
Design 78 patients without diabetes: 38 received Slavinorm (5 mg intramuscularly, twice weekly for five weeks) plus baseline care, and 40 received pentoxifylline plus baseline care. The paper leaves randomization and masking unspecified.
Important limitations
- Randomization and masking are not established. Comparator percentages do not consistently translate into integer counts out of 40. Short-term surrogate and walking outcomes do not establish fewer amputations or cardiovascular events.
- The quoted p values in the paper are not all between-arm tests. The comparison does not establish a general vascular or longevity benefit.
Cardiology and Cardiovascular Surgery. 18(1):102–108 · Original clinical journal publication
Randomized study in people · 2026
Vascular polypeptides plus troxerutin in chronic venous disease: randomized trial
- VCSS, visit 4
- 2.33±1.31 versus 3.24±1.62; reported difference −0.92 points (95% CI −1.34 to −0.50), p<0.001.
- CIVIQ-20 improvement ≥5 points, visit 4
- 93.7% versus 75.8%; p=0.0006.
- Serious adverse events
- None reported in the abstract; nonserious-event counts unavailable.
The abstract reports lower venous severity with adjunctive polypeptides than placebo.
Study notes · methods, sources and limitations
Participants or model 190 randomized participants, 95 per arm; both arms received troxerutin
Design 190 participants in a double-blind randomized comparison; 95 per arm; troxerutin in both arms. Bovine-vessel polypeptide complex; brand not named in the abstract.
Important limitations
- Full formulation, participant flow, prespecification and detailed harms require the paper. No serious adverse events reported does not mean no adverse events. This adjunctive venous trial is separate from the arterial trials and does not establish purified KED efficacy.
- Visit 4 was 30±3 days after treatment ended. The rounded displayed means subtract to −0.91; retain the authors’ −0.92 estimate. The abstract leaves the analysis methods and trade-name identity unclear.
Journal of Venous Disorders / Flebologiya. 20(2):89–96 · Original clinical journal publication
About Vasolin / Slavinorm
Names in this research collection
Slavinorm · Vascular polypeptide complex
Research background
This vascular polypeptide profile includes trials of injectable Slavinorm and reports on bovine-vessel extracts. Slavinorm studies measured pain-free walking and recovery after vascular surgery.
More study findings
Comparison in people · 2026
Slavinorm after above-knee femoropopliteal bypass: twelve-month comparison
- Ankle–brachial index
- Baseline 0.46 / 0.44; twelve months 0.80 / 0.65.
- Pain-free walking distance
- Baseline 31.5 / 23 m; twelve months 138 / 66 m.
- Restenosis as printed
- 7 (11.6%) versus 15 (50%).
Walking distance and ankle–brachial index were higher in the adjunctive group at twelve months; the abstract contains inconsistent restenosis figures.
Author affiliations · Ryazan State Medical University
More reported outcomes
- Bypass thrombosis
- 1 (3.3%) versus 4 (13.3%).
Study notes · methods, sources and limitations
Participants or model 60 postoperative patients, 30 per arm; Fontaine III–IV disease
Design 60 postoperative patients, 30/30; Slavinorm plus standard care versus standard care.
Important limitations
- Randomization and masking not established; baseline walking differed and both arms underwent surgery. Seven cases are printed as 11.6%, inconsistent with 30 participants. The odds-ratio narrative also needs reconciliation. No established mortality, amputation or purified-KED benefit.
- Seven of 30 is 23.3%, so the printed percentage is inconsistent. Reported p<0.001 changes are not verified treatment-by-time effects; no pooled risk estimate calculated.
Angiology and Vascular Surgery. 2026;32(1):28–35. PMID 42289061 · Original clinical journal publication
Animal research · 2025
Vessel polypeptides and vascular markers in rabbits of different ages: 2025 conference abstract
- Vascular markers and plaque
- Favorable findings reported; no numerical treatment effect extracted.
Vascular-marker and plaque findings were reported in an age-stratified rabbit experiment.
Study notes · methods, sources and limitations
Participants or model 40 rabbits: four groups of ten, each with five young and five older animals
Design 40 rabbits, four groups of ten; five young and five older animals per group. Vessel-derived polypeptides; exact brand not confirmed.
Important limitations
- Conference-level animal evidence; related 2024 work may share animals. Immunostaining does not demonstrate prostacyclin synthesis or a causal mechanism. No human efficacy or equivalence with purified KED established.
- Conference evidence; possible overlap with 2024 experiments. Staining signals do not establish a mechanism or human benefit.
Kazakhstan gerontology and geriatrics conference, Astana, 10 October 2025; pp.35–36 · Original conference abstract; not a full journal article
Review of earlier studies · 2026
Review connects vascular extracts, KED and AEDR experimental research
Study of multiple preparations
- Preparations reviewed
- Vascular polypeptide preparation, KED and AEDR
- Endothelial findings
- KED restored elevated ET-1 expression toward normal in reported culturesCultures derived from patients are not a clinical treatment trial
- Cardiac findings
- AEDR experimental cardioprotection summarizedAnimal experiments; no new human trial
The review brings together vascular polypeptide, KED and AEDR research. It describes changes in endothelial endothelin-1 expression, vascular hemodynamics and experimental myocardial injury. These preparation-specific observations are preclinical; the review supplies no new human cardiovascular efficacy trial.
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
Study notes · methods, sources and limitations
Participants or model Review of vascular-polypeptide, KED and AEDR experiments in endothelial cultures and animal cardiovascular models.
Important limitations
- Review of earlier experiments, not independent replication. Vascular extracts, KED and AEDR are different preparations; effects cannot be transferred between them. Exact publication day is not supplied by the index; newly indexed 28 October 2026.
Advances in gerontology = Uspekhi gerontologii 39(4) · Journal publication
- Compound class
- Tissue-derived polypeptide complex
- Research collection
- Peptide bioregulation · editorial grouping
- Institutions in linked studies
- St. Petersburg Institute of Bioregulation and Gerontology · Pavlov Institute of Physiology, Russian Academy of Sciences · Institute of Toxicology, Federal Medical-Biological Agency · Ryazan State Medical University
- Source review
- Review dates and the material assessed are listed with each publication below.
Understanding the evidence
Human research
108-person arterial randomized trial; 190-person venous randomized report; separate 78- and 58-person comparisons; 60-person postoperative follow-up through 12 months
Study methods
Original abstracts and a full HTML comparison; trial methods, formulation and harms still need review
Independent replication
Distinct populations and preparations; independent confirmation and cohort checks remain necessary
Source access
Original society/publisher records; full papers pending for several trials
Safety evidence
Short-term reports; no safety-equivalence or long-term vascular-event conclusion
Open a topic for the evidence assessment.
Patents and claimed inventions
These 1 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.
Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →
Findings by study
Animal research · 2017
Slavinorm and cortical microcirculation in older hypertensive rats
Cortical microvessel density was about 1.7 times that of untreated hypertensive rats two months after one course. Perfusion rose but remained below that of normotensive rats.
Pial microvessel density · About 1.7 times the untreated hypertensive group and 1.8 times the normotensive group.
Study notes and original source
Slavinorm and cortical microcirculation in older hypertensive rats
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology · Pavlov Institute of Physiology, Russian Academy of Sciences
Slavinorm, calf-vessel polypeptide complex
Format: Original journal PDF · Reviewed: See scope
I. B. Sokolova, I. V. Sergeev, G. A. Ryzhak, V. Kh. Khavinson, L. S. Kozina · Advances in Gerontology. 30(4):534–537
Cortical microvessel density was about 1.7 times that of untreated hypertensive rats two months after one course. Perfusion rose but remained below that of normotensive rats.
Results and tables
Reported findings and study design
Three groups of 12-month-old male rats: 12 treated SHR, 19 untreated SHR, and 10 normotensive Wistar–Kyoto controls. 0.25 mg per rat intramuscularly, once daily for five days, followed by a two-day break and five more injections. Measurements in the sensorimotor cortex were taken two months after treatment.
Population or model 41 male rats: 12 treated hypertensive, 19 untreated hypertensive, 10 normotensive controls
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Pial microvessel density | About 1.7 times the untreated hypertensive group and 1.8 times the normotensive group. | |
| Artery and arteriole density | About 1.7 times the untreated hypertensive group and 2.3 times the normotensive group. | |
| Cortical perfusion and oxygenation | Both increased versus untreated hypertensive rats. Perfusion stayed below the normotensive group. |
The paper names the St. Petersburg Institute of Bioregulation and Gerontology as the developer and lists Pavlov Institute of Physiology as a coauthor affiliation. Animal overlap with the related 2017 paper is unclear.
Source for these results ↗ · Reviewed 2026-11-16
- Population / setting
- 41 male rats: 12 treated hypertensive, 19 untreated hypertensive, 10 normotensive controls
- Source reviewed
- Original methods and results, including Figures 1–3.
Study limitations
- The methods leave randomization and masking unspecified.
- The two 2017 publications share investigators and closely related experiments. Animal reuse is unclear.
Reviewed 2026-11-16.
Animal research · 2017
Slavinorm and cortical microcirculation after one or two courses in hypertensive rats
After two courses, older rats had about 1.6 times the cortical microvessel density and about 15% higher perfusion than untreated hypertensive rats of the same age.
Pial microvessel density versus age-matched untreated SHR · About 1.2 times as high after one course in younger rats and 1.6 times as high after two courses in older rats.
Study notes and original source
Slavinorm and cortical microcirculation after one or two courses in hypertensive rats
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology · Pavlov Institute of Physiology, Russian Academy of Sciences
Slavinorm, calf-vessel polypeptide complex
Format: Original journal PDF · Reviewed: See scope
I. B. Sokolova, G. A. Ryzhak, V. Kh. Khavinson · Advances in Gerontology. 30(5):671–675
After two courses, older rats had about 1.6 times the cortical microvessel density and about 15% higher perfusion than untreated hypertensive rats of the same age.
Results and tables
Reported findings and study design
Four SHR groups: 6 untreated and 14 treated at the 6-month assessment, 6 untreated and 14 treated at the 12-month assessment. A normotensive group provided a reference. 0.25 mg per rat intramuscularly, once daily for five days, followed by a two-day break and five more injections. The younger group received one course at 4 months. The older group received courses at 4 and 10 months. Measurements were taken two months after the last course.
Population or model Four groups of hypertensive male rats (6, 14, 6 and 14), with a normotensive reference group
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Pial microvessel density versus age-matched untreated SHR | About 1.2 times as high after one course in younger rats and 1.6 times as high after two courses in older rats. | |
| Perfusion after one course | 23.8 ± 1.3 versus 25.1 ± 1.1 perfusion units in untreated and treated younger rats, respectively. The difference was statistically nonsignificant. | |
| Perfusion after two courses | About 15% above untreated older SHR and below the normotensive reference group. |
The authors compared treated and untreated rats at each age. The treatment-course comparison also differs by age, and animal overlap with the related 2017 paper is unclear.
Source for these results ↗ · Reviewed 2026-11-16
- Population / setting
- Four groups of hypertensive male rats (6, 14, 6 and 14), with a normotensive reference group
- Source reviewed
- Original methods, group table and results for cortical vessel density, perfusion and oxygen saturation.
Study limitations
- The one- and two-course treatment groups were assessed at different ages.
- The two 2017 reports may share animals. The studies measured local cortical blood flow in rats.
Reviewed 2026-11-16.
Experiment described in a patent · 2024
Slavinorm: critical limb-ischemia method — RU2827088C1
Both cases reportedly improved after combined care, but bypass thrombosis or loss of bypass function also occurred during follow-up.
Case 1: walking and ankle–brachial index · Walking distance increased from 10 m to 700 m; affected-leg ABI increased from 0.32 to 0.70 · Before versus after surgery and multidrug care · 5 months
Study notes and original source
Slavinorm: critical limb-ischemia method — RU2827088C1
Patent-defined substance or composition · Patent publication
Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Евгений Петрович Кривощеков, Владислав Павлович Компаниец, Владислав Евгеньевич Романов, Николай Александрович Лысов, Максим Вячеславович Яшков, Дмитрий Валерьевич Роднянский · RU2827088C1 · patent family RU2827088C1
Both cases reportedly improved after combined care, but bypass thrombosis or loss of bypass function also occurred during follow-up.
Results and tables
Reported patent results
Reported findings
Both cases reportedly improved after combined care, but bypass thrombosis or loss of bypass function also occurred during follow-up.
Two illustrative patients with diabetes and critical limb ischemia received bypass surgery, multiple medicines and adjunctive Slavinorm.
Population or model Two illustrative patients with diabetes and critical limb ischemia received bypass surgery, multiple medicines and adjunctive Slavinorm.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Case 1: walking and ankle–brachial index | Walking distance increased from 10 m to 700 m; affected-leg ABI increased from 0.32 to 0.70 | Before versus after surgery and multidrug care · 5 months |
| Case 2: walking and ankle–brachial index | Walking distance reported as 800 m; affected-leg ABI increased from 0.27 to 0.80 | Before versus after combined care · 4 months |
| Case 2: later deterioration | Bypass thrombosis; walking distance fell to 300 m, without reported critical ischemia | Earlier 800 m result was not fully maintained · 1 year |
Two uncontrolled cases cannot isolate Slavinorm from surgery or concurrent medicines. The text also contains inconsistent calendar dates. Proposed angiogenesis mechanisms are not independently established.
Source for these results ↗ · Reviewed 2026-11-06
- Population / setting
- Two illustrative patients with diabetes and critical limb ischemia received bypass surgery, multiple medicines and adjunctive Slavinorm.
- Source reviewed
- Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
- The combined-care claim is not a controlled estimate of Slavinorm's independent effect and does not prove equivalence to a synthetic vascular peptide.
- Two uncontrolled cases cannot isolate Slavinorm from surgery or concurrent medicines. The text also contains inconsistent calendar dates. Proposed angiogenesis mechanisms are not independently established.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Reviewed 2026-11-06.
Comparison in people · 2026
Slavinorm after above-knee femoropopliteal bypass: twelve-month comparison
Walking distance and ankle–brachial index were higher in the adjunctive group at twelve months; the abstract contains inconsistent restenosis figures.
Ankle–brachial index · Baseline 0.46 / 0.44; twelve months 0.80 / 0.65.
Study notes and original source
Slavinorm after above-knee femoropopliteal bypass: twelve-month comparison
Author affiliations · Ryazan State Medical University
Slavinorm bovine-vessel polypeptide complex plus standard care · Original clinical journal publication
Format: Original publisher abstract · Reviewed: Abstract only. Full tables unavailable.
I. A. Suchkov, A. V. Lyasheva, V. O. Povarov, R. E. Kalinin, I. V. Vezenova · Angiology and Vascular Surgery. 2026;32(1):28–35. PMID 42289061
Walking distance and ankle–brachial index were higher in the adjunctive group at twelve months; the abstract contains inconsistent restenosis figures.
Results and tables
Reported findings and study design
60 postoperative patients, 30/30; Slavinorm plus standard care versus standard care.
Population or model 60 postoperative patients, 30 per arm; Fontaine III–IV disease
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Ankle–brachial index | Baseline 0.46 / 0.44; twelve months 0.80 / 0.65. | |
| Pain-free walking distance | Baseline 31.5 / 23 m; twelve months 138 / 66 m. | |
| Restenosis as printed | 7 (11.6%) versus 15 (50%). | |
| Bypass thrombosis | 1 (3.3%) versus 4 (13.3%). |
Seven of 30 is 23.3%, so the printed percentage is inconsistent. Reported p<0.001 changes are not verified treatment-by-time effects; no pooled risk estimate calculated.
Source for these results ↗ · Reviewed 2026-11-06
- Population / setting
- 60 postoperative patients, 30 per arm; Fontaine III–IV disease
- Source reviewed
- Publisher abstract; follow-up at 1, 3, 6, 9 and 12 months.
Study limitations
- Randomization and masking not established; baseline walking differed and both arms underwent surgery.
- Seven cases are printed as 11.6%, inconsistent with 30 participants. The odds-ratio narrative also needs reconciliation.
- No established mortality, amputation or purified-KED benefit.
Reviewed 2026-11-06.
Animal research · 2025
Vessel polypeptides and vascular markers in rabbits of different ages: 2025 conference abstract
Vascular-marker and plaque findings were reported in an age-stratified rabbit experiment.
Study notes and original source
Vessel polypeptides and vascular markers in rabbits of different ages: 2025 conference abstract
Vessel-derived polypeptide preparation; Slavinorm brand not verified · Original conference abstract; not a full journal article
Format: Organizer-hosted proceedings PDF · Reviewed: Selected abstract text, pp. 35–36
A. G. Sopromadze, D. S. Medvedev, N. S. Linkova, A. V. Borodulin, V. O. Polyakova · Kazakhstan gerontology and geriatrics conference, Astana, 10 October 2025; pp.35–36
Vascular-marker and plaque findings were reported in an age-stratified rabbit experiment.
Results and tables
Reported findings and study design
40 rabbits, four groups of ten; five young and five older animals per group. Vessel-derived polypeptides; exact brand not confirmed.
Population or model 40 rabbits: four groups of ten, each with five young and five older animals
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Vascular markers and plaque | Favorable findings reported; no numerical treatment effect extracted. |
Conference evidence; possible overlap with 2024 experiments. Staining signals do not establish a mechanism or human benefit.
Source for these results ↗ · Reviewed 2026-11-06
- Population / setting
- 40 rabbits: four groups of ten, each with five young and five older animals
- Source reviewed
- Original conference abstract, distinct from adjacent narrative reviews; no individual DOI verified.
Study limitations
- Conference-level animal evidence; related 2024 work may share animals.
- Immunostaining does not demonstrate prostacyclin synthesis or a causal mechanism.
- No human efficacy or equivalence with purified KED established.
Reviewed 2026-11-06.
Randomized study in people · 2023
Slavinorm for intermittent claudication: randomized placebo-controlled trial
Pain-free walking distance rose 46.2% and 31.4% in the two Slavinorm groups versus 6.5% with placebo.
Study notes and original source
Slavinorm for intermittent claudication: randomized placebo-controlled trial
Slavinorm, bovine-vessel polypeptide complex · Original clinical journal publication
Format: Original society-hosted issue abstracts · Reviewed: Complete original abstract checked; full article pending
I. A. Suchkov, R. E. Kalinin, N. D. Mzhavanadze, A. A. Kamaev, A. G. Burenin, R. N. Larkov · Angiology and Vascular Surgery. 29(1):23–33
Pain-free walking distance rose 46.2% and 31.4% in the two Slavinorm groups versus 6.5% with placebo.
Results and tables
Reported findings and study design
Seven-center, double-blind trial with 108 randomized participants. The two Slavinorm groups (36 each) received 5 mg intramuscularly twice or three times weekly for 10 injections. The two placebo groups (18 each) followed the matching schedules.
Population or model 108 randomized patients; active groups 36/36, placebo groups 18/18
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Pain-free walking distance | Active arms: +46.2% and +31.4%; placebo: +6.5%. | |
| At least 50% walking-distance improvement | 28% and 26% in active arms versus 3% with placebo; exact analysis denominators unavailable. | |
| Adverse-event comparison | p=0.59983; event counts absent. |
The abstract reports one placebo result across two placebo arms and provides no pooling method. Follow-up lasted up to 91 days. Long-term walking outcomes and detailed adverse-event counts are unavailable in the abstract.
Source for these results ↗ · Reviewed 2026-11-06
- Population / setting
- 108 randomized patients; active groups 36/36, placebo groups 18/18
- Source reviewed
- Original journal abstract; four-arm design and selected outcomes checked.
Study limitations
- The abstract does not resolve analysis populations, placebo pooling, allocation concealment or missing data.
- No exact primary-outcome p value or confidence interval is supplied.
- A nonsignificant adverse-event comparison does not establish safety equivalence.
Reviewed 2026-11-06.
Comparison in people · 2025
Slavinorm in peripheral arterial atherosclerosis: 78-patient comparison
At three months the ankle–brachial index was 0.8 with Slavinorm and 0.7 with pentoxifylline. In the Slavinorm group, 22 of 38 participants walked 35–40 m farther.
Study notes and original source
Slavinorm in peripheral arterial atherosclerosis: 78-patient comparison
Slavinorm; comparator received baseline care and pentoxifylline · Original clinical journal publication
Format: Original publisher HTML · Reviewed: Methods and selected results narrative checked
I. I. Katelnitsky, E. S. Katelnitskaya · Cardiology and Cardiovascular Surgery. 18(1):102–108
At three months the ankle–brachial index was 0.8 with Slavinorm and 0.7 with pentoxifylline. In the Slavinorm group, 22 of 38 participants walked 35–40 m farther.
Results and tables
Reported findings and study design
78 patients without diabetes: 38 received Slavinorm (5 mg intramuscularly, twice weekly for five weeks) plus baseline care, and 40 received pentoxifylline plus baseline care. The paper leaves randomization and masking unspecified.
Population or model 78 patients: 38 Slavinorm plus baseline care, 40 comparator; diabetes excluded
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Ankle–brachial index | Both groups: 0.7→0.8 at two months; at three months active remained 0.8, comparator fell to 0.7. | |
| Walking distance in active group | 22/38 gained 35–40 m; 4/38 unchanged. The paper prints the range for the remaining 12 participants in reverse order. | |
| Harms | Authors report no adverse reactions; ascertainment and longer follow-up remain unresolved. |
The quoted p values in the paper are not all between-arm tests. The comparison does not establish a general vascular or longevity benefit.
Source for these results ↗ · Reviewed 2026-11-06
- Population / setting
- 78 patients: 38 Slavinorm plus baseline care, 40 comparator; diabetes excluded
- Source reviewed
- Original HTML methods, results and references; no independent reanalysis.
Study limitations
- Randomization and masking are not established.
- Comparator percentages do not consistently translate into integer counts out of 40.
- Short-term surrogate and walking outcomes do not establish fewer amputations or cardiovascular events.
Reviewed 2026-11-06.
Randomized study in people · 2026
Vascular polypeptides plus troxerutin in chronic venous disease: randomized trial
The abstract reports lower venous severity with adjunctive polypeptides than placebo.
VCSS, visit 4 · 2.33±1.31 versus 3.24±1.62; reported difference −0.92 points (95% CI −1.34 to −0.50), p<0.001.
Study notes and original source
Vascular polypeptides plus troxerutin in chronic venous disease: randomized trial
Bovine-vessel polypeptide complex; brand not named in the abstract · Original clinical journal publication
Format: Original publisher abstract; full article behind purchase access · Reviewed: Complete original abstract checked
I. A. Suchkov, A. A. Kamaev, A. V. Chupin, S. V. Sapelkin, A. G. Burenin · Journal of Venous Disorders / Flebologiya. 20(2):89–96
The abstract reports lower venous severity with adjunctive polypeptides than placebo.
Results and tables
Reported findings and study design
190 participants in a double-blind randomized comparison; 95 per arm; troxerutin in both arms. Bovine-vessel polypeptide complex; brand not named in the abstract.
Population or model 190 randomized participants, 95 per arm; both arms received troxerutin
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| VCSS, visit 4 | 2.33±1.31 versus 3.24±1.62; reported difference −0.92 points (95% CI −1.34 to −0.50), p<0.001. | |
| CIVIQ-20 improvement ≥5 points, visit 4 | 93.7% versus 75.8%; p=0.0006. | |
| Serious adverse events | None reported in the abstract; nonserious-event counts unavailable. |
Visit 4 was 30±3 days after treatment ended. The rounded displayed means subtract to −0.91; retain the authors’ −0.92 estimate. The abstract leaves the analysis methods and trade-name identity unclear.
Source for these results ↗ · Reviewed 2026-11-06
- Population / setting
- 190 randomized participants, 95 per arm; both arms received troxerutin
- Source reviewed
- Original abstract; a manufacturer Slavinorm attribution is separate from the unnamed preparation in this abstract.
Study limitations
- Full formulation, participant flow, prespecification and detailed harms require the paper.
- No serious adverse events reported does not mean no adverse events.
- This adjunctive venous trial is separate from the arterial trials and does not establish purified KED efficacy.
Reviewed 2026-11-06.
Comparison in people · 2026
Vascular polypeptides during rehabilitation after myocardial infarction with type 2 diabetes
In 58 patients after myocardial infarction, median pain-free walking distance at day 50 was 260 vs 190 m with Slavinorm plus rehabilitation versus rehabilitation alone. Six of 29 Slavinorm recipients had injection-site pain.
Study notes and original source
Vascular polypeptides during rehabilitation after myocardial infarction with type 2 diabetes
Slavinorm 5 mg bovine-vessel polypeptide lyophilizate for intramuscular injection. · Original clinical journal publication
Format: Original publisher full text · Reviewed: Methods, selected tables and adverse events checked
M. A. Simonyan, L. A. Marchenkova, V. A. Vasileva · Bulletin of Rehabilitation Medicine. 25(2):8–22
In 58 patients after myocardial infarction, median pain-free walking distance at day 50 was 260 vs 190 m with Slavinorm plus rehabilitation versus rehabilitation alone. Six of 29 Slavinorm recipients had injection-site pain.
Results and tables
Reported findings and study design
Open prospective comparison in 58 patients with type 2 diabetes and leg atherosclerosis after myocardial infarction, 29 per arm. Both arms received rehabilitation.
Population or model 58 patients: 29 adjunctive polypeptides plus rehabilitation, 29 rehabilitation alone; conducted in 2025
Dose, route and schedule
Slavinorm 5 mg intramuscularly twice weekly for five weeks (10 injections). Both groups received cardiometabolic rehabilitation. Assessments were at baseline, day 15 and day 50.
Protocol source ↗ · Original publisher full text, methods, Tables 3–4 and adverse events
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Pain-free walking distance · day 50 | 260 vs 190 m | Slavinorm plus rehabilitation versus rehabilitation alone. Baseline medians 180 and 175 m. · Table 4 marks p < 0.001 between groups at day 50. |
| Walking Impairment Questionnaire · day 50 | 65 vs 47 points | Baseline medians 45 and 44. · Table 4 marks p < 0.001 between groups at day 50. |
| Timed Up and Go · day 50 | 8.5 vs 9.6 seconds | Baseline medians 10.0 and 9.8 seconds. · Table 3 marks p < 0.01 between groups at day 50. |
| Barthel Index · day 50 | 100.0 vs 94.2 points | Both arms improved from baseline. The table does not mark a day 50 between-arm difference. |
| Injection-site pain | 6/29 (20.7%) | The investigators report no serious adverse events, systemic allergic reactions or early discontinuations attributed to the study drug. |
Table 4 · walking outcomes
| Measure | Time | Slavinorm + rehabilitation | Rehabilitation |
|---|---|---|---|
| Pain-free distance (m) | Baseline | 180 [150–220] | 175 [145–215] |
| Pain-free distance (m) | Day 15 | 210 [180–250] | 185 [155–225] |
| Pain-free distance (m) | Day 50 | 260 [220–300] | 190 [160–230] |
| WIQ score | Baseline | 45 [38–52] | 44 [37–51] |
| WIQ score | Day 15 | 55 [48–62] | 46 [39–53] |
| WIQ score | Day 50 | 65 [58–72] | 47 [40–54] |
Median [interquartile interval]. The narrative says control distance stopped increasing after day 15. Table 4 gives 185 m at day 15 and 190 m at day 50. Values here follow the table.
The comparison was open and the allocation method is unclear. These endpoint comparisons concern adjunctive injected Slavinorm during rehabilitation.
Source for these results ↗ · Reviewed 2026-11-13
- Population / setting
- 58 patients: 29 adjunctive polypeptides plus rehabilitation, 29 rehabilitation alone; conducted in 2025
- Source reviewed
- Original publisher full text, methods, Tables 3–4 and adverse events
Study limitations
- Open prospective comparison. The paper describes two comparable groups and does not document random assignment or concealment.
- Multiple outcomes were tested in a small short-term study. The published narrative and some table entries disagree. The source page preserves those discrepancies.
Reviewed 2026-11-13.
Review of earlier studies · 2026
Peptidergic regulation of age-related alterations in the cardiovascular system
The review brings together vascular polypeptide, KED and AEDR research. It describes changes in endothelial endothelin-1 expression, vascular hemodynamics and experimental myocardial injury. These preparation-specific observations are preclinical; the review supplies no new human cardiovascular efficacy trial.
Study notes and original source
Peptidergic regulation of age-related alterations in the cardiovascular system
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
· Journal publication
Ryzhak GA, Popovich IG, Kozina LS, Arutionov VA, Arutjunyan AV · Advances in gerontology = Uspekhi gerontologii 39(4)
The review brings together vascular polypeptide, KED and AEDR research. It describes changes in endothelial endothelin-1 expression, vascular hemodynamics and experimental myocardial injury. These preparation-specific observations are preclinical; the review supplies no new human cardiovascular efficacy trial.
Results and tables
Reported findings and study design
The review brings together vascular polypeptide, KED and AEDR research. It describes changes in endothelial endothelin-1 expression, vascular hemodynamics and experimental myocardial injury. These preparation-specific observations are preclinical; the review supplies no new human cardiovascular efficacy trial.
Population or model Review of vascular-polypeptide, KED and AEDR experiments in endothelial cultures and animal cardiovascular models.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Preparations reviewed | Vascular polypeptide preparation, KED and AEDR | |
| Endothelial findings | KED restored elevated ET-1 expression toward normal in reported cultures | Cultures derived from patients are not a clinical treatment trial |
| Cardiac findings | AEDR experimental cardioprotection summarized | Animal experiments; no new human trial |
Review of earlier experiments, not independent replication. Vascular extracts, KED and AEDR are different preparations; effects cannot be transferred between them. Exact publication day is not supplied by the index; newly indexed 28 October 2026.
Source for these results ↗ · Reviewed 2026-10-31
- Population / setting
- Review of vascular-polypeptide, KED and AEDR experiments in endothelial cultures and animal cardiovascular models.
- Source reviewed
- Primary publication metadata and indexed abstract checked through Europe PMC on 31 October 2026. No unavailable effect sizes inferred.
Study limitations
- Review of earlier experiments, not independent replication. Vascular extracts, KED and AEDR are different preparations; effects cannot be transferred between them. Exact publication day is not supplied by the index; newly indexed 28 October 2026.
Reviewed 2026-10-31.
Review of earlier studies · 2019
Polypeptide vessel complex and its role in physiology function regulation in aging pathology
Reviews calf-vessel extract Slavinorm/Vasolin, including lipid metabolism, hemostasis and vessel-wall repair.
Study notes and original source
Polypeptide vessel complex and its role in physiology function regulation in aging pathology
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
Kuznik BI, Ryzhak GA, Khavinson VK · Adv Gerontol 32(1-2):174-179. PMID 31228385
Reviews calf-vessel extract Slavinorm/Vasolin, including lipid metabolism, hemostasis and vessel-wall repair.
- Population / setting
- Animal models of vascular and age-associated pathology
- Source reviewed
- Indexed abstract and citation checked via Europe PMC / PubMed; full methods and risk of bias not appraised.
Study limitations
- This record concerns the tissue extract, not isolated KED/Vesugen.
- Animal findings and a narrative review do not establish human vascular benefit.
Reviewed 2026-09-29.
Laboratory analysis · 2020
Identification of short peptides in the composition of polypeptide complexes isolated from animal organs
Reports KED in vessel complex, AED in cartilage, EDG and AEDL in bronchial mucosa, EDR in brain and KEDW in pancreas. This strengthens sequence-level links in the research program.
Study notes and original source
Identification of short peptides in the composition of polypeptide complexes isolated from animal organs
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology · Pavlov Institute of Physiology, Russian Academy of Sciences · Institute of Toxicology, Federal Medical-Biological Agency
I. K. Zhurkovich, N. G. Kovrov, G. A. Ryzhak, E. S. Mironova, V. Kh. Khavinson · Uspekhi Sovremennoi Biologii 140(2):140–148
Reports KED in vessel complex, AED in cartilage, EDG and AEDL in bronchial mucosa, EDR in brain and KEDW in pancreas. This strengthens sequence-level links in the research program.
Results and tables
Reported findings and study design
UHPLC–tandem mass spectrometry of six lyophilized animal-tissue complexes, using reference standards for seven target sequences.
Population or model Animal-organ polypeptide complexes analyzed by UHPLC–MS
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| EDG and AEDL in the bronchial mucosa complex | EDG 0.028% and AEDL 0.060% of the analyzed extract |
Identified short peptides by extract
| Extract | Sequence | Reported proportion |
|---|---|---|
| Bronchial mucosa | EDG | 0.028% |
| Bronchial mucosa | AEDL | 0.060% |
| Vessels | KED | 0.020% |
| Cartilage | AED | 0.020% |
| Brain | EDR | 0.024% |
| Pancreas | KEDW | 0.035% |
These measurements describe the analyzed preparations. The paper does not characterize all constituents or identify the clinical trial batch.
Source for these results ↗ · Reviewed 2026-11-15
- Population / setting
- Animal-organ polypeptide complexes analyzed by UHPLC–MS
- Source reviewed
- Original analytical paper, test method, Table 3 and chromatograms in Figures 1–6.
Study limitations
- Molecular detection does not prove identical pharmacology or clinical equivalence.
- The paper’s discussion of clinical work is not an independent clinical trial.
Reviewed 2026-11-15.
Related compound research
Follow shared publications or research classes. These links do not establish equivalent effects between compounds.
Research collection curated by @PepMariner · editorial standards. Send a source correction ↗
Browse bibliography & PDFs ↗